Related Experiment Videos
[Pneumococcal vaccine effectiveness in the elderly. Systematic review and meta-analysis].
J Puig-Barberà1, A Belenguer Varea, M Goterris Pinto
1Grupo de Trabajo de Vacunas de la Sociedad Valenciana de Medicina de Familia y Comunitaria (SVMFYC). Promoción de Salud. Centro de Salud Pública de Castellón. Spain. jpuigb@terra.es
Atencion Primaria
|October 10, 2002
Summary
This study found no strong evidence that the pneumococcal vaccine prevents Streptococcus pneumoniae illness in the elderly. Further research is needed to confirm vaccine effectiveness in this population.
Area of Science:
- Epidemiology
- Immunology
- Public Health
Background:
- Pneumococcal disease remains a significant health concern for the elderly population.
- Vaccination is a primary strategy for preventing infectious diseases, including those caused by Streptococcus pneumoniae.
- Assessing the effectiveness of the pneumococcal vaccine in older adults is crucial for public health policy.
Purpose of the Study:
- To systematically review and analyze the available evidence on the effectiveness of the pneumococcal vaccine in preventing Streptococcus pneumoniae illness in the elderly.
- To estimate the vaccine effectiveness (VE) against pneumococcal pneumonia and invasive pneumococcal disease in older individuals.
Main Methods:
- A comprehensive systematic review and meta-analysis of clinical trials, cohort studies, and case-control studies.
- Searched MEDLINE, EMBASE, and the Cochrane Library for relevant studies published between 1964 and 2000.
- Studies were independently assessed for validity by four investigators using predefined criteria.
Main Results:
- Analysis of pneumococcal pneumonia showed a relative risk (RR) of 0.86 (95% CI, 0.24 to 2.99), with a vaccine effectiveness of 14% (95% CI, -199 to 76%).
- For invasive pneumococcal disease caused by vaccine serotypes, the RR was 0.68 (95% CI, 0.39-1.18), indicating a vaccine effectiveness of 32% (95% CI, 18-61%) in studies meeting quality criteria.
- However, only one study fully met all inclusion and quality criteria for pneumonia, and a limited number of high-quality studies were available for invasive disease.
Conclusions:
- The current evidence does not strongly support the effectiveness of the pneumococcal vaccine in reducing or preventing Streptococcus pneumoniae illness in the elderly population.
- The findings highlight the need for more rigorous studies to definitively establish the vaccine's role in this demographic.
- Further investigation is warranted to understand potential variations in vaccine response and to optimize prevention strategies for pneumococcal disease in older adults.